graves; thyroid eye disease; had pain in her arms; she also felt sick like had the flu for about 24 hours; eye pain; ear pain; dry eye; EYE PRESSURE; the first was done on 31Jul2021/the second dose was on 13Aug2021; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A 43-year-old female patient received BNT162b2 (BNT162B2), on 13Aug2021 as dose 2, single (Lot number: EW0169) at the age of 39 years for covid-19 immunisation. The patient’s relevant medical history included: “asthma attacks”, start date: 2019 (unspecified if ongoing); “throwing up” (unspecified if ongoing). The patient’s concomitant medications were not reported. Past drug history included: Metoprolol for blood pressure, reaction(s): “asthma attack”; Metoprolol for blood pressure, reaction(s): “phlegm”; Metoprolol for blood pressure, reaction(s): “spasms”; Metoprolol for blood pressure, reaction(s): “vasomotor reaction”. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Lot number: EW0158), administration date: 31Jul2021, when the patient was 39-year-old, for Covid-19 immunization, reaction(s): “had pain in her arms”, “she also felt sick like had the flu for about 24 hours”. The following information was reported: GRAVES’ DISEASE (medically significant), outcome “unknown”, described as “graves”; ENDOCRINE OPHTHALMOPATHY (medically significant), outcome “unknown”, described as “thyroid eye disease”; PAIN IN EXTREMITY (non-serious), outcome “unknown”, described as “had pain in her arms”; INFLUENZA LIKE ILLNESS (non-serious), outcome “unknown”, described as “she also felt sick like had the flu for about 24 hours”; EYE PAIN (non-serious), outcome “unknown”; EAR PAIN (non-serious), outcome “unknown”; DRY EYE (non-serious), outcome “unknown”; OCULAR DISCOMFORT (non-serious), outcome “unknown”, described as “EYE PRESSURE”; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome “unknown”, described as “the first was done on 31Jul2021/the second dose was on 13Aug2021”. The patient underwent the following laboratory tests and procedures: Anti-thyroid antibody: (02Nov2021) 98.9; Blood thyroid stimulating hormone: (02Nov2021) 1.72; SARS-CoV-2 test: (06Jan2022) Positive; Thyroid function test: (unspecified date) graves disease and thyroid eye disease; Thyroxine: (02Nov2021) 1.0. Therapeutic measures were taken as a result of graves’ disease (methimazole).; Sender’s Comments: Linked Report(s) : US-PFIZER INC-202500020504 same patient, different event, different dose of vaccine;